FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation, involving changes or additions to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Carcinoid Syndrome
• Vipoma

Drugs mentioned

• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

SUPPL AP for SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)